TLPPFTelix Pharmaceutical Ltd.

About Telix Pharmaceutical Ltd. (TLPPF)

Telix Pharmaceutical Ltd. (TLPPF) is a Biotechnology company headquartered in North Melbourne, VA, Australia whose shares trade over-the-counter on the Pink tier.

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy.

TLPPF key facts

Ticker symbol

TLPPF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

North Melbourne, VA, Australia

Country of incorporation

AU

Estimated market cap

$4.69B (as of Apr 11, 2025)

Shares outstanding

282,205,557

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

12/31

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with T